Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Texas Southwestern Medical Center
The study is a prospective phase II, single arm, open label trial evaluating Stereotactic Ablative Radiation Therapy (SAbR) for patients with oligo-progressive RCC (Renal Cell Cancer). Problem Statements: * Can local therapy (SAbR) for oligoprogression delay the change of systemic therapy if progression is minimal to the progressive sites? * Safely delaying the change of systemic therapy can have significant quality of life benefits for patients with oligo-progressive RCC. * Can SAbR potentially improve progression free survival in oligoprogressive RCC patients? Primary Endpoint: • Time to change of systemic therapy. Secondary Endpoint: * PFS on subsequent systemic therapy (PFS-SST) after progression on SAbR. * Overall survival(OS). * Toxicity, safety and tolerance. * Impact on health-related quality of life (HRQoL). Sample Size: 20 Patients Statistical Analysis: Time to event will be estimated using the Kaplan-Meier approach along with the 95% confidence interval.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted